A Phase I/II, multi-center, open-label study of BEZ235, administered orally on a continuous daily dosing schedule in adult patients with advanced solid malignancies including patients with advanced breast cancer.

Trial Profile

A Phase I/II, multi-center, open-label study of BEZ235, administered orally on a continuous daily dosing schedule in adult patients with advanced solid malignancies including patients with advanced breast cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Dactolisib (Primary) ; Trastuzumab
  • Indications Advanced breast cancer; Solid tumours
  • Focus Adverse reactions; Biomarker
  • Sponsors Novartis
  • Most Recent Events

    • 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Oct 2012 Planned End Date changed from 1 Oct 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
    • 01 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top